论文部分内容阅读
目的:评价肝硬化低蛋白血症患者应用重组人生长激素(rhGH)的有效性、安全性和经济性。方法:计算机检索中国生物医学文献数据库(CBM)、万方医学、维普医药、Embase、PubMed、Cochrane Library等数据库2000年1月1日至2019年1月1日收录的随机对照试验，按照一定标准纳入排除，并使用RevMan 5.3软件进行统计分析。结果:13篇文献纳入Meta分析，共739例患者。结果表明，与人血白蛋白(HAS)相比，rhGH治疗肝硬化低蛋白血症的短期疗效差异无统计学意义[加权均数差(WMD)为-0.42，95%n CI(-1.77，0.92)，n P＝0.54]，但中远期疗效则更好[WMD为3.42，95%n CI(0.13，6.70)，n P＝0.04；WMD为7.12，95%n CI(4.75，9.50)，n P<0.001]。n 结论:应用rhGH治疗肝硬化低蛋白血症的短期疗效与输注HSA相当，但药效维持时间明显延长，无明显不良反应，且更具经济性。“,”Objective:To evaluate the efficacy, safety and economy of recombinant human growth hormone (rhGH) in the treatment of patients with liver cirrhosis and hypoproteinemia.Methods:Computer search for randomized controlled trials included in Chinese Biomedical Literature Database(CBM), Wanfang Medicine, Weipu Medicine, Embase, PubMed, Cochrane Library and other databases from January 1, 2000 to January 1, 2019, and excluded according to certain criteria.RevMan5.3 software was used for statistical analysis.Results:A total of 13 articles were included in the meta-analysis, a total of 739 patients.The results showed that the short-term efficacy of rhGH in the treatment of cirrhosis with hypoproteinemia had no statistically significant difference compared with human serum albumin (HSA)[WMD=-0.42, 95%n CI(-1.77, 0.92), n P=0.54], but the mid-and long-term effects of rhGH were better[WMD=3.42, 95%n CI(0.13, 6.70), n P=0.04; WMD=7.12, 95%n CI(4.75, 9.50), n P<0.001].n Conclusion:The application of rhGH in the treatment of cirrhosis with hypoproteinemia is equivalent to the infusion of HSA in short-term efficacy, but the duration of treatment is prolonged, has no obvious adverse reactions, and is more economical.